Tumor Purity Adjusted Beta Values Improve Biological Interpretability of High-dimensional DNA Methylation Data

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Sep 9

PMID 36084090

Authors

Johan Staaf

Mattias Aine

Affiliations

Soon will be listed here.

Abstract

A common issue affecting DNA methylation analysis in tumor tissue is the presence of a substantial amount of non-tumor methylation signal derived from the surrounding microenvironment. Although approaches for quantifying and correcting for the infiltration component have been proposed previously, we believe these have not fully addressed the issue in a comprehensive and universally applicable way. We present a multi-population framework for adjusting DNA methylation beta values on the Illumina 450/850K platform using generic purity estimates to account for non-tumor signal. Our approach also provides an indirect estimate of the aggregate methylation state of the surrounding normal tissue. Using whole exome sequencing derived purity estimates and Illumina 450K methylation array data generated by The Cancer Genome Atlas project (TCGA), we provide a demonstration of this framework in breast cancer illustrating the effect of beta correction on the aggregate methylation beta value distribution, clustering accuracy, and global methylation profiles.

Citing Articles

Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer.

Hohmann L, Sigurjonsdottir K, Campos A, Nacer D, Veerla S, Rosengren F Nat Commun. 2025; 16(1):2208.

PMID: 40044693 PMC: 11882987. DOI: 10.1038/s41467-025-57419-z.

Tumor purity estimated from bulk DNA methylation can be used for adjusting beta values of individual samples to better reflect tumor biology.

Sasiain I, Nacer D, Aine M, Veerla S, Staaf J NAR Genom Bioinform. 2024; 6(4):lqae146.

PMID: 39498434 PMC: 11532792. DOI: 10.1093/nargab/lqae146.

Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.

Liang W, Lu R, Jayasinghe R, Foltz S, Porta-Pardo E, Geffen Y Cancer Cell. 2023; 41(9):1567-1585.e7.

PMID: 37582362 PMC: 11613269. DOI: 10.1016/j.ccell.2023.07.013.

References

Lauss M, Aine M, Sjodahl G, Veerla S, Patschan O, Gudjonsson S . DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics. 2012; 7(8):858-67. PMC: 3427281. DOI: 10.4161/epi.20837. View

Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K . Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9. PMC: 4016708. DOI: 10.1093/bioinformatics/btu049. View

Zhang N, Wu H, Zhang W, Wang J, Wu H, Zheng X . Predicting tumor purity from methylation microarray data. Bioinformatics. 2015; 31(21):3401-5. DOI: 10.1093/bioinformatics/btv370. View

Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

Wainer Katsir K, Linial M . Human genes escaping X-inactivation revealed by single cell expression data. BMC Genomics. 2019; 20(1):201. PMC: 6419355. DOI: 10.1186/s12864-019-5507-6. View

Zheng X, Zhang N, Wu H, Wu H . Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies. Genome Biol. 2017; 18(1):17. PMC: 5267453. DOI: 10.1186/s13059-016-1143-5. View

Moore J, Purcaro M, Pratt H, Epstein C, Shoresh N, Adrian J . Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature. 2020; 583(7818):699-710. PMC: 7410828. DOI: 10.1038/s41586-020-2493-4. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

Teschendorff A, Breeze C, Zheng S, Beck S . A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinformatics. 2017; 18(1):105. PMC: 5307731. DOI: 10.1186/s12859-017-1511-5. View

10.

Arneson D, Yang X, Wang K . MethylResolver-a method for deconvoluting bulk DNA methylation profiles into known and unknown cell contents. Commun Biol. 2020; 3(1):422. PMC: 7400544. DOI: 10.1038/s42003-020-01146-2. View

11.

Corces M, Granja J, Shams S, Louie B, Seoane J, Zhou W . The chromatin accessibility landscape of primary human cancers. Science. 2018; 362(6413). PMC: 6408149. DOI: 10.1126/science.aav1898. View

12.

Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reutersward C . Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020; 11(1):3747. PMC: 7385112. DOI: 10.1038/s41467-020-17537-2. View

13.

Benelli M, Romagnoli D, Demichelis F . Tumor purity quantification by clonal DNA methylation signatures. Bioinformatics. 2018; 34(10):1642-1649. PMC: 5946863. DOI: 10.1093/bioinformatics/bty011. View

14.

Jaffe A, Irizarry R . Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 2014; 15(2):R31. PMC: 4053810. DOI: 10.1186/gb-2014-15-2-r31. View

15.

Zhou W, Laird P, Shen H . Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2016; 45(4):e22. PMC: 5389466. DOI: 10.1093/nar/gkw967. View

16.

Zheng X, Zhao Q, Wu H, Li W, Wang H, Meyer C . MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. Genome Biol. 2014; 15(8):419. PMC: 4165374. DOI: 10.1186/s13059-014-0419-x. View

17.

Zhang W, Li Z, Wei N, Wu H, Zheng X . Detection of differentially methylated CpG sites between tumor samples with uneven tumor purities. Bioinformatics. 2019; 36(7):2017-2024. DOI: 10.1093/bioinformatics/btz885. View

18.

Zheng S, Breeze C, Beck S, Teschendorff A . Identification of differentially methylated cell types in epigenome-wide association studies. Nat Methods. 2018; 15(12):1059-1066. PMC: 6277016. DOI: 10.1038/s41592-018-0213-x. View

19.

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View

20.

Moran S, Arribas C, Esteller M . Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics. 2015; 8(3):389-99. PMC: 4864062. DOI: 10.2217/epi.15.114. View